On Sept. 16, the U.S. Food and Drug Administration (FDA) approved the first generic version of Xeloda (capecitabine), used to treat metastatic breast and colorectal cancer. Read more.
© 2019 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder